Effect of Intravitreal Aflibercept on Central Retinal Arterial Blood Flow in Type 1 Retinopathy of Prematurity

Abstract

Purpose

To evaluate the blood flow changes of the central retinal artery measured with color Doppler imaging (CDI) in infants receiving intravitreal aflibercept (IVA) for treatment of type 1 retinopathy of prematurity (ROP).

Methods

Patients with type 1 ROP were assessed prospectively by CDI following IVA. Color Doppler imaging was used to measure the peak systolic velocity, end diastolic velocity (EDV), pulsatility index (PI), and resistivity index (RI) of the central retinal artery (CRA) before IVA injection and 1 hour, 1 week, and 1 month after injection.

Results

A total of 29 eyes of 15 infants were included in this study. The mean gestational age at birth was 28.62 ± 2.48 weeks and the mean birthweight was 1,198.62 ± 348.99 g. All treated eyes showed complete regression of ROP and peripheral retinal vascularization continued. Measurements of EDV-CRA, RI-CRA, and PI-CRA showed significant changes after IVA treatment.

Conclusions

This study showed that IVA is an effective treatment for type 1 ROP. After IVA treatment, vascular resistance increases, ocular blood flow decreases, and changes in hemodynamic parameters of CRA may remain for a month. Further studies are needed to evaluate the effect of anti-vascular endothelial growth factor agents on ocular hemodynamics in infants with ROP.

Keywords

Aflibercept Blood flow Central retinal artery Intravitreal Retinopathy of prematurity

Get full access to this article

View all access options for this article.

References

Steinkuller

Gilbert

Foster

Collins

Coats

Childhood blindness.

J AAPOS. 1999;3(1):26–32.

Kwinta

Bik-Multanowski

Mitkowska

Tomasik

Pietrzyk

The clinical role of vascular endothelial growth factor (VEGF) system in the pathogenesis of retinopathy of prematurity.

Graefes Arch Clin Exp Ophthalmol. 2008;246(10):1467–1475.

Mintz-Hittner

Kennedy

Chuang

BEAT-ROP Cooperative Group.

Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;364(7):603–615.

Yetik

Gunay

Sirop

Salihoglu

Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.

Graefes Arch Clin Exp Ophthalmol. 2014;14(334-):339.

Zhou

Zheng

Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.

Curr Eye Res. 2015;18:1–6.

Hoerster

Muether

Dahlke

et al.

Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.

Acta Ophthalmol. 2013;91(1):e74–e75.

Autrata

Krejcírová

Senková

Holoušová

Doležel

Borek

Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II.

Eur J Ophthalmol. 2012;22(5):687–694.

Papadopoulos

Martin

Ruan

et al.

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab.

Angiogenesis. 2012;15(2):171–185.

Salman

Said

Structural, visual and refractive outcomes of intravitreal aflibercept injection in high-risk prethreshold type 1 retinopathy of prematurity.

Ophthalmic Res. 2015;53(1):15–20.

10.

Holland

Saunders

Kagemann

et al.

Color doppler imaging of the central retinal artery in premature infants undergoing examination for retinopathy of prematurity.

J AAPOS. 1999;3(4):194–198.

11.

Papacci

Romagnoli

Favuzzi

et al.

Doppler ultrasound of blood flow velocities in ophthalmic and central retinal arteries during the early neonatal period.

Am J Ophthalmol. 1998;126(5):691–697.

12.

Romagnoli

Papacci

Zecca

Giannantonio

De Carolis

Tortorolo

Normal neonatal values of ophthalmic and central retinal artery blood flow velocities.

J Pediatr Ophthalmol Strabismus. 2001;38(4):213–217.

13.

Niwald

Grałek

Evaluation of blood flow in the ophthalmic artery and central retinal artery in children with retinopathy of prematurity.

Klin Oczna. 2006;108(1-3):32–35.

14.

Hartenstein

Müller

Metze

Czernik

Bührer

Blood flow assessed by color Doppler imaging in retinopathy of prematurity.

J Perinatol. 2015;35(9):745–747.

15.

Neely

Harris

Hynes

et al.

Longitudinal assessment of plus disease in retinopathy of prematurity using color Doppler imaging.

J AAPOS. 2009;13(5):509–511.

16.

Toklu

Cakmak

Raza

Anayol

Asik

Simşek

Short-term effects of intravitreal bevacizumab (Avastin(^®)) on retrobulbar hemodynamics in patients with neovascular age-related macular degeneration.

Acta Ophthalmol. 2011;89(1):e41–e45.

17.

Shahin

Gad

Hamza

Impact of intravitreal triamcinolone acetonide versus intravitreal bevacizumab on retrobulbar hemodynamic in patients with diabetic macular edema.

Cutan Ocul Toxicol. 2014;33(1):49–53.

18.

Günay

Tuten

Sancak

et al.

Effect of Single Intravitreal Bevacizumab on Ophthalmic and Middle Cerebral Arterial Blood Flow in Retinopathy of Prematurity.

Ophthalmic Res. 2016;55(4):165–171.

19.

Early Treatment For Retinopathy Of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the early treatment for retinopathy of prematurity randomized trial.

Arch Ophthalmol. 2003;121(12):1684–1694.

20.

Bonnin

Pournaras

JAC

Makowiecka

et al.

Ultrasound assessment of ocular vascular effects of repeated intravitreal injections of ranibizumab for wet age-related macular degeneration.

Acta Ophthalmol. 2014;92(5):e382–e387.

21.

Shimomura

Hirata

Ishikawa

Okinami

Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection.

Graefes Arch Clin Exp Ophthalmol. 2009;247(8):1089–1094.

22.

Hartnett

Pathophysiology and mechanisms of severe retinopathy of prematurity.

Ophthalmology. 2015;122(1):200–210.

23.

Zaleski

Liu

Brock

Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries.

Am J Physiol. 1993;265(2 Pt 2):H586–H592.

24.

Tilton

Chang

LeJeune

Stephan

Brock

Williamson

Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.

Invest Ophthalmol Vis Sci. 1999;40(3):689–696.